The fully linked HTML version of this article has now been published.
JCS ePress
online publication date 15 Aug 2006
doi: 10.1242/jcs.03145
Research Article
Validating Aurora B as an anti-cancer drug target
Fiona Girdler,
Karen E. Gascoigne,
Patrick A. Eyers,
Sonya Hartmuth,
Claire Crafter,
Kevin M. Foote,
Nicholas J. Keen,
and
Stephen S. Taylor*
* Author for correspondence (e-mail: stephen.taylor{at}manchester.ac.uk)
The Aurora kinases, a family of mitotic regulators, have received much attention as potential targets for novel anti-cancer therapeutics. Several Aurora kinase inhibitors have been described including ZM447439, which prevents chromosome alignment, spindle checkpoint function and cytokinesis. Subsequently, ZM447439-treated cells exit mitosis without dividing and lose viability. Because ZM447439 inhibits both Aurora A and B, we set out to determine which phenotypes are due to inhibition of which kinase. Using molecular genetic approaches, we show that inhibition of Aurora B kinase activity phenocopies ZM447439. Furthermore, a novel ZM compound, which is 100 times more selective for Aurora B over Aurora A in vitro, induces identical phenotypes. Importantly, inhibition of Aurora B kinase activity induces a penetrant anti-proliferative phenotype, indicating that Aurora B is an attractive anti-cancer drug target. Using molecular genetic and chemical-genetic approaches, we also probe the role of Aurora A kinase activity. We show that simultaneous repression of Aurora A plus induction of a catalytic mutant induces a monopolar phenotype. Consistently, another novel ZM-related inhibitor, which is 20 times as potent against Aurora A compared with ZM447439, induces a monopolar phenotype. Expression of a drug-resistant Aurora A mutant reverts this phenotype, demonstrating that Aurora A kinase activity is required for spindle bipolarity in human cells. Because small molecule-mediated inhibition of Aurora A and Aurora B yields distinct phenotypes, our observations indicate that the Auroras may present two avenues for anti-cancer drug discovery.
This article has been cited by other articles:
|
|
|
|
 
Y. G. Lin, A. Immaneni, W. M. Merritt, L. S. Mangala, S. W. Kim, M. M.K. Shahzad, Y. T.M. Tsang, G. N. Armaiz-Pena, C. Lu, A. A. Kamat, et al.
Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth
Clin. Cancer Res.,
September 1, 2008;
14(17):
5437 - 5446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Swain, J. Ding, J. Wu, and G. D. Smith
Regulation of spindle and chromatin dynamics during early and late stages of oocyte maturation by aurora kinases
Mol. Hum. Reprod.,
May 1, 2008;
14(5):
291 - 299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. D'Alise, G. Amabile, M. Iovino, F. P. Di Giorgio, M. Bartiromo, F. Sessa, F. Villa, A. Musacchio, and R. Cortese
Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1140 - 1149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Walsby, V. Walsh, C. Pepper, A. Burnett, and K. Mills
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts
Haematologica,
May 1, 2008;
93(5):
662 - 669.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Gautschi, J. Heighway, P. C. Mack, P. R. Purnell, P. N. Lara Jr., and D. R. Gandara
Aurora Kinases as Anticancer Drug Targets
Clin. Cancer Res.,
March 15, 2008;
14(6):
1639 - 1648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Barr and F. Gergely
Aurora-A: the maker and breaker of spindle poles
J. Cell Sci.,
September 1, 2007;
120(17):
2987 - 2996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hoar, A. Chakravarty, C. Rabino, D. Wysong, D. Bowman, N. Roy, and J. A. Ecsedy
MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to Aneuploidy
Mol. Cell. Biol.,
June 15, 2007;
27(12):
4513 - 4525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. LeRoy, J. J. Hunter, K. M. Hoar, K. E. Burke, V. Shinde, J. Ruan, D. Bowman, K. Galvin, and J. A. Ecsedy
Localization of Human TACC3 to Mitotic Spindles Is Mediated by Phosphorylation on Ser558 by Aurora A: A Novel Pharmacodynamic Method for Measuring Aurora A Activity
Cancer Res.,
June 1, 2007;
67(11):
5362 - 5370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. T. Keady, P. Kuo, S. E. Martinez, L. Yuan, and L. E. Hake
MAPK interacts with XGef and is required for CPEB activation during meiosis in Xenopus oocytes
J. Cell Sci.,
March 15, 2007;
120(6):
1093 - 1103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Manfredi, J. A. Ecsedy, K. A. Meetze, S. K. Balani, O. Burenkova, W. Chen, K. M. Galvin, K. M. Hoar, J. J. Huck, P. J. LeRoy, et al.
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
PNAS,
March 6, 2007;
104(10):
4106 - 4111.
[Abstract]
[Full Text]
[PDF]
|
|
|
© The Company of Biologists Ltd 2006
